Zentalis Pharmaceuticals Inc Quick Ratio (ZNTL) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Zentalis Pharmaceuticals Inc   (NASDAQ: ZNTL)

Zentalis Pharmaceuticals Inc 's Quick Ratio

ZNTL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.66 below Zentalis Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 382 other companies have achieved higher Quick Ratio than Zentalis Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 732, from total ranking in the first quarter 2026 at 788.

Explain Quick Ratio?
How much Cash & cash equivalents ZNTL´s has?
What are ZNTL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ZNTL Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -3.36 % -28.72 % -30.66 % -32.27 % -41.49 %
Y / Y Cash & cash equivalent Change -91.35 % -33.89 % -30.13 % 573.5 % 675.21 %
Quick Ratio MRQ 0.66 6.01 6.73 7.49 7.35
ZNTL's Total Ranking # 732 # 788 # 667 # 671 # 766
Seq. Current Liabilities Change 7.02 % -3.62 % -1.64 % -4.75 % -21.06 %
Seq. Cash & cash equivalent Change -88.3 % -13.88 % -11.64 % -2.91 % -10.51 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 383
Healthcare Sector # 704
Overall Market # 2374


Quick Ratio Statistics
High Average Low
15.37 7.03 0.55
(Sep 30 2020)   (Jun 30 2024)




Financial Statements
Zentalis Pharmaceuticals Inc 's Current Liabilities $ 38 Millions Visit ZNTL's Balance sheet
Zentalis Pharmaceuticals Inc 's Cash & cash equivalent $ 25 Millions Visit ZNTL's Balance sheet
Source of ZNTL's Sales Visit ZNTL's Sales by Geography


Cumulative Zentalis Pharmaceuticals Inc 's Quick Ratio

ZNTL's Quick Ratio for the trailling 12 Months

ZNTL Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -25.19 % -33.85 % -29.21 % -28.65 % -22.81 %
Y / Y Cash & cash equivalent TTM Growth -23.94 % 36.25 % 141.79 % 106.59 % -6.89 %
Quick Ratio TTM 5.19 6.91 6.97 6.94 5.1
Total Ranking TTM # 1316 # 1532 # 1262 # 1357 # 1492
Seq. Current Liabilities TTM Growth -0.89 % -8.75 % -9.06 % -9.03 % -12.37 %
Seq. Cash & cash equivalent TTM Growth -25.61 % -9.6 % -8.57 % 23.69 % 33.27 %

Quick ratio ranking by company, industry and sector >> Back to ZNTL Financial Strength Comparisons >> Go to Compare ZNTL Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ZNTL's Current Liabilities to $37.71 millions, cumulative Quick Ratio to 5.19 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Zentalis Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3438.

Explain Quick Ratio?
How much Cash & cash equivalents ZNTL´s has?
What are ZNTL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 437
Healthcare Sector # 896
Within the Market # 732


trailing twelve months Quick Ratio Statistics
High Average Low
3.61 1.32 0.59
(Dec 31 2020)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Fortress Biotech Inc   1.81 $ 196.576  Millions$ 108.829  Millions
Maravai Lifesciences Holdings Inc   1.77 $ 70.091  Millions$ 39.519  Millions
Decoy Therapeutics Inc   1.77 $ 8.289  Millions$ 4.680  Millions
Hyperion Defi inc   1.75 $ 9.637  Millions$ 5.509  Millions
Verastem Inc   1.75 $ 136.400  Millions$ 78.130  Millions
Urogen Pharma Ltd   1.74 $ 108.000  Millions$ 61.915  Millions
Pyxis Oncology Inc   1.72 $ 47.141  Millions$ 27.474  Millions
Ernexa Therapeutics Inc   1.71 $ 5.028  Millions$ 2.932  Millions
Lantern Pharma Inc   1.70 $ 7.361  Millions$ 4.323  Millions
Nuvectis Pharma inc   1.67 $ 22.160  Millions$ 13.294  Millions
Quoin Pharmaceuticals Ltd   1.63 $ 10.800  Millions$ 6.613  Millions
Mallinckrodt Plc  1.63 $ 1,075.800  Millions$ 660.600  Millions
Macrogenics Inc   1.59 $ 173.305  Millions$ 108.815  Millions
Fibrobiologics Inc   1.59 $ 3.515  Millions$ 2.213  Millions
Sarepta Therapeutics Inc   1.57 $ 788.489  Millions$ 502.908  Millions
Revium Rx.  1.55 $ 1.506  Millions$ 0.971  Millions
Liquidia Corporation  1.50 $ 284.181  Millions$ 189.298  Millions
Greenwich Lifesciences Inc   1.50 $ 8.876  Millions$ 5.923  Millions
Arcutis Biotherapeutics Inc   1.49 $ 238.552  Millions$ 160.340  Millions
Mirum Pharmaceuticals Inc   1.48 $ 330.728  Millions$ 222.788  Millions
Regeneron Pharmaceuticals Inc   1.45 $ 7,994.600  Millions$ 5,530.600  Millions
Imunon Inc   1.44 $ 6.900  Millions$ 4.779  Millions
Zai Lab Limited  1.44 $ 617.522  Millions$ 428.584  Millions
Mannkind Corporation  1.44 $ 205.271  Millions$ 142.898  Millions
Kyntra Bio Inc   1.41 $ 50.644  Millions$ 36.040  Millions
Medicus Pharma Ltd   1.40 $ 15.174  Millions$ 10.841  Millions
Aurinia Pharmaceuticals Inc   1.39 $ 179.732  Millions$ 129.084  Millions
Omeros Corporation  1.39 $ 131.953  Millions$ 94.963  Millions
Avenue Therapeutics Inc   1.38 $ 1.942  Millions$ 1.407  Millions
Royalty Pharma Plc  1.33 $ 836.986  Millions$ 630.928  Millions

Date modified: 2026-09-05T15:41:29+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.